The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. (February 2016)
- Record Type:
- Journal Article
- Title:
- The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. (February 2016)
- Main Title:
- The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
- Authors:
- Englund, Amir
Atakan, Zerrin
Kralj, Aleksandra
Tunstall, Nigel
Murray, Robin
Morrison, Paul - Abstract:
- Rationale: Cannabis is mostly grown under illegal and unregulated circumstances, which seems to favour a product increasingly high in its main cannabinoid ∆-9-tetrahydrocannabinol (THC). ∆-9-tetrahydrocannabivarin (THCV) is a relatively untested cannabinoid which is said to be a cannabinoid receptor neutral antagonist, and may inhibit the effects of THC. Objectives: To explore the safety and tolerability of repeated THCV administration and its effects on symptoms normally induced by THC in a sample of healthy volunteers. Methods: Ten male cannabis users (<25 use occasions) were recruited for this within-subjects, placebo-controlled, double-blind, cross-over pilot study. 10mg oral pure THCV or placebo were administered daily for five days, followed by 1mg intravenous THC on the fifth day. Results: THCV was well tolerated and subjectively indistinguishable from placebo. THC did not significantly increase psychotic symptoms, paranoia or impair short-term memory, while still producing significant intoxicating effects. Delayed verbal recall was impaired by THC and only occurred under placebo condition ( Z =-2.201, p =0.028), suggesting a protective effect of THCV. THCV also inhibited THC-induced increased heart rate ( Z =-2.193, p =0.028). Nine out of ten participants reported THC under THCV condition (compared to placebo) to be subjectively weaker or less intense (χ 2 =6.4, p =0.011). THCV in combination with THC significantly increased memory intrusions ( Z =-2.155, p =0.031).Rationale: Cannabis is mostly grown under illegal and unregulated circumstances, which seems to favour a product increasingly high in its main cannabinoid ∆-9-tetrahydrocannabinol (THC). ∆-9-tetrahydrocannabivarin (THCV) is a relatively untested cannabinoid which is said to be a cannabinoid receptor neutral antagonist, and may inhibit the effects of THC. Objectives: To explore the safety and tolerability of repeated THCV administration and its effects on symptoms normally induced by THC in a sample of healthy volunteers. Methods: Ten male cannabis users (<25 use occasions) were recruited for this within-subjects, placebo-controlled, double-blind, cross-over pilot study. 10mg oral pure THCV or placebo were administered daily for five days, followed by 1mg intravenous THC on the fifth day. Results: THCV was well tolerated and subjectively indistinguishable from placebo. THC did not significantly increase psychotic symptoms, paranoia or impair short-term memory, while still producing significant intoxicating effects. Delayed verbal recall was impaired by THC and only occurred under placebo condition ( Z =-2.201, p =0.028), suggesting a protective effect of THCV. THCV also inhibited THC-induced increased heart rate ( Z =-2.193, p =0.028). Nine out of ten participants reported THC under THCV condition (compared to placebo) to be subjectively weaker or less intense (χ 2 =6.4, p =0.011). THCV in combination with THC significantly increased memory intrusions ( Z =-2.155, p =0.031). Conclusion: In this first study of THC and THCV, THCV inhibited some of the well-known effects of THC, while potentiating others. These findings need to be interpreted with caution due to a small sample size and lack of THC-induced psychotomimetic and memory-impairing effect, probably owing to the choice of dose. … (more)
- Is Part Of:
- Journal of psychopharmacology. Volume 30:Number 2(2016:Feb.)
- Journal:
- Journal of psychopharmacology
- Issue:
- Volume 30:Number 2(2016:Feb.)
- Issue Display:
- Volume 30, Issue 2 (2016)
- Year:
- 2016
- Volume:
- 30
- Issue:
- 2
- Issue Sort Value:
- 2016-0030-0002-0000
- Page Start:
- 140
- Page End:
- 151
- Publication Date:
- 2016-02
- Subjects:
- THCV -- THC -- Δ9-tetrahydrocannabivarin -- Δ9-tetrahydrocannabinol -- cannabis -- memory -- psychosis -- cannabinoid -- human
Psychopharmacology -- Periodicals
615.78 - Journal URLs:
- http://jop.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/0269881115615104 ↗
- Languages:
- English
- ISSNs:
- 0269-8811
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6577.xml